I am a
Home I AM A Search Login

Papers of the Week

Papers: 26 Mar 2022 - 1 Apr 2022


2022 Mar 25


Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.


Diener H C, McAllister P, Jürgens TP, Kessler Y, Ning X, Cohen JM, Ramirez Campos V, Barash S, Silberstein SD
Cephalalgia. 2022 Mar 25:3331024221076485.
PMID: 35331009.


Fremanezumab, a fully humanized monoclonal antibody that selectively targets calcitonin gene-related peptide, has demonstrated efficacy for preventive treatment of episodic and chronic migraine. Since calcitonin gene-related peptide is expressed within the cardio- and cerebrovascular system and may have cardioprotective effects, it is critical to understand the cardio- and cerebrovascular safety of fremanezumab.